From Tissue to Treatment

Prostate cancer is the most common cancer in men in Europe.

Precision oncology's promise depends on biomarker testing.

HRR alterations affect many metastatic prostate cancer patients.

Localized testing practices are essential across fragmented healthcare systems.

Digital workflows improve testing efficiency and outcomes.

Rethinking testing timing can enhance sample quality.

Liquid biopsy offers a minimally invasive option for genetic information.

Continuous education and standardized processes are crucial.